MINE in the context of chemotherapy is an acronym for one of the chemotherapy regimens used for Medical case management, treatment of relapsed or refractory disease, refractory aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Today this regimen is often combined with monoclonal antibody rituximab. In this case the regimen is called R-MINE or MINE-R.
The [R]-MINE regimen consists of:
# Rituximab - CD20, anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant cell, malignant ones;
# Mesna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration;
# Ifosfamide - an alkylating antineoplastic agent from oxazafosforine group;
# Mitoxantrone - a synthetic anthracycline analogue (anthraquinone) that is able to intercalation (biochemistry), intercalate DNA and thus prevent cell division (mitosis);
# Etoposide - a topoisomerase inhibitor.
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
/ref>
Dosing regimen
References
{{Reflist
Chemotherapy regimens used in lymphoma